Enlivex Therapeutics LtdNASDAQ:ENLV
- LAST PRICE1.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1000/ 3
- Ask / Lots1.4400/ 7
- Open / Previous Close0.0000 / 1.4000
- Day Range---
- 52 Week Range
- Volume1
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENLV |
|---|---|---|
| 09:32 ET | 2154 | 1.5 |
| 09:34 ET | 760 | 1.5005 |
| 09:36 ET | 1507 | 1.5 |
| 09:38 ET | 1333 | 1.5 |
| 09:39 ET | 1000 | 1.51 |
| 09:41 ET | 3360 | 1.5 |
| 09:45 ET | 2400 | 1.49 |
| 09:48 ET | 637 | 1.4999 |
| 09:50 ET | 178 | 1.4951 |
| 09:54 ET | 300 | 1.495 |
| 09:57 ET | 4700 | 1.49 |
| 09:59 ET | 600 | 1.5 |
| 10:01 ET | 785 | 1.49 |
| 10:03 ET | 1500 | 1.48 |
| 10:06 ET | 285 | 1.462 |
| 10:08 ET | 2390 | 1.46 |
| 10:10 ET | 1800 | 1.44 |
| 10:14 ET | 100 | 1.44 |
| 10:17 ET | 468 | 1.445 |
| 10:19 ET | 100 | 1.445 |
| 10:24 ET | 100 | 1.46 |
| 10:28 ET | 700 | 1.4557 |
| 10:32 ET | 289 | 1.44 |
| 10:33 ET | 240 | 1.42 |
| 10:35 ET | 1782 | 1.4 |
| 10:37 ET | 382 | 1.4001 |
| 10:44 ET | 1344 | 1.4195 |
| 10:51 ET | 100 | 1.47 |
| 10:57 ET | 100 | 1.4 |
| 11:02 ET | 1083 | 1.4224 |
| 11:09 ET | 5000 | 1.4499 |
| 11:11 ET | 200 | 1.43 |
| 11:18 ET | 100 | 1.45 |
| 11:27 ET | 200 | 1.45 |
| 11:29 ET | 300 | 1.425 |
| 11:31 ET | 1000 | 1.4498 |
| 11:38 ET | 400 | 1.44 |
| 11:42 ET | 2294 | 1.425 |
| 11:45 ET | 4250 | 1.43 |
| 11:47 ET | 100 | 1.45 |
| 11:58 ET | 100 | 1.43 |
| 12:00 ET | 2197 | 1.43 |
| 12:09 ET | 4998 | 1.4001 |
| 12:12 ET | 354 | 1.4293 |
| 12:14 ET | 100 | 1.43 |
| 12:18 ET | 183 | 1.415 |
| 12:32 ET | 100 | 1.43 |
| 12:38 ET | 100 | 1.43 |
| 12:39 ET | 100 | 1.43 |
| 12:50 ET | 100 | 1.43 |
| 01:03 ET | 100 | 1.43 |
| 01:08 ET | 100 | 1.43 |
| 01:15 ET | 100 | 1.43 |
| 01:26 ET | 100 | 1.43 |
| 01:46 ET | 1589 | 1.39 |
| 01:48 ET | 200 | 1.39 |
| 01:50 ET | 558 | 1.39 |
| 02:02 ET | 100 | 1.41 |
| 02:08 ET | 196 | 1.4 |
| 02:13 ET | 300 | 1.41 |
| 02:27 ET | 600 | 1.395 |
| 02:29 ET | 2200 | 1.4 |
| 02:33 ET | 100 | 1.4 |
| 02:45 ET | 300 | 1.4 |
| 02:49 ET | 100 | 1.44 |
| 03:00 ET | 492 | 1.39 |
| 03:16 ET | 100 | 1.44 |
| 03:23 ET | 200 | 1.44 |
| 03:32 ET | 7294 | 1.44 |
| 03:39 ET | 1200 | 1.39 |
| 03:43 ET | 100 | 1.44 |
| 03:48 ET | 100 | 1.44 |
| 03:52 ET | 100 | 1.44 |
| 03:54 ET | 200 | 1.4 |
| 03:56 ET | 251 | 1.41 |
| 03:57 ET | 100 | 1.41 |
| 03:59 ET | 1782 | 1.4 |
Apr 16, 2024
Apr 12, 2024
DJ Enlivex Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 6:53AM ET on Friday Apr 12, 2024 by Dow Jones
6:53AM ET on Friday Apr 12, 2024 by Dow Jones
Apr 11, 2024
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra(TM) In Patients with Sepsis, from 2:58PM ET on Thursday Apr 11, 2024 by Dow Jones
2:58PM ET on Thursday Apr 11, 2024 by Dow JonesEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With Sepsis, from 8:05AM ET on Thursday Apr 11, 2024 by Dow Jones
8:05AM ET on Thursday Apr 11, 2024 by Dow Jones
Mar 22, 2024
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV, from 10:52AM ET on Friday Mar 22, 2024 by Dow Jones
10:52AM ET on Friday Mar 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enlivex Therapeutics Ltd | 26.0M | -0.9x | --- |
Neurosense Therapeutics Ltd | 26.3M | -2.0x | --- |
UNITY Biotechnology Inc | 25.3M | -0.5x | --- |
BioVie Inc | 26.8M | -0.4x | --- |
Sensei Biotherapeutics Inc | 24.6M | -0.8x | --- |
Nymox Pharmaceutical Corp | 28.0M | -5.6x | --- |
Company Information
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Contact Information
- Headquarters
- 14 Einstein St.NESS-ZIONA, Israel 7403618
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer
- Oren Hershkovitz
- Executive Chairman of the Board
- Shai Novik
- Founder, Chief Scientific Officer and Medical Officer
- Dror Mevorach
- Chief Financial Officer
- Shachar Shlosberger
- Director
- Baruch Halpert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
